News

Chemtex builds biorefinery
Enlarge image

BusinessDenmarkItaly

Chemtex builds biorefinery

24.08.2012 - The US government will support Novozymes's partner Chemtex Inc. in its aim to construct a cellulosic ethanol plant in North Carolina by backing a US$99m loan.

The plant is expected to be located in Sampson County, North Carolina and produce 20 million gallons (76 million liters) of bioethanol per year from up to 600,000 tons of non-food grasses. The enzymes necessary for processing the biomass will be provided by Danish biotech company Novozymes (Baegsvaard). The construction is set to begin in late 2012. “Realising a commercial scale cellulosic ethanol plant in the United States and proving that it can produce cost competitive sustainable ethanol is an important milestone in the commercialisation process of advanced biofuels,” said Guido Ghisolfi, President of the Chemtex Group, which is a unit of the Italian chemical company Grupo Mossi & Ghisolfi.http://www.gruppomg.com/history.php?mi=201 

Slated to open in 2014, the plant will employ approximately 65 employees and indirectly generate 250 more jobs in the community, not including construction jobs. The feedstock will be grown on low productivity/marginal land that is in part being utilised as “spray fields” for the hog farming industry. Wilmington, North Carolina-based Chemtex received US$3.9m from the US Department of Agriculture in Junehttp://www.chemtex.com/templates/news_20120613.html to grow more than 4,000 acres of miscanthus and switchgrass, which will now be used as feedstock. Chemtex and Novozymes have already started a collaboration this April aimed at building the world’s first industrial plant for fermentation of second generation bioethanol from cheap straw feeds.

http://www.european-biotechnology-news.com/news/news/2012-03/chemtex-builds-biorefinery.html

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

European UnionUKEU

24.06.2016 After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.

Investment FundUKIrelandEULuxembourg

24.06.2016 UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.

ImmunotherapyFranceEU

22.06.2016 TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Science’s tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.

Clinical TrialsUK

21.06.2016 Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.

R&DSwitzerlandUK

16.06.2016 With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.

FinancingEUNetherlands

14.06.2016 European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.

AwardEUPortugalGermanyDenmarkFrance

09.06.2016 Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.04 CHF33.33%
  • EVOCUTIS (UK)0.05 GBP25.00%
  • MOBERG PHARMA (S)36.80 SEK13.58%

FLOP

  • RENEURON (UK)2.62 GBP-9.03%
  • WILEX (D)1.75 EUR-5.41%
  • CO.DON (D)2.73 EUR-5.21%

TOP

  • THERAMETRICS (CH)0.04 CHF33.3%
  • ABCAM (UK)770.00 GBP19.0%
  • MDX HEALTH (B)3.78 EUR15.2%

FLOP

  • SARTORIUS (D)70.00 EUR-71.8%
  • CIRCASSIA LIMITED (L)101.60 GBP-61.9%
  • VALNEVA (F)2.09 EUR-36.3%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)26.50 SEK1753.1%
  • NICOX (F)12.00 EUR545.2%

FLOP

  • BB BIOTECH (D)41.41 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.58 SEK-78.0%
  • EVOCUTIS (UK)0.05 GBP-77.3%

No liability assumed, Date: 30.06.2016